Repro Med Valuation
| KRMD Stock | USD 4.37 0.30 6.42% |
At this time, the company appears to be undervalued. Repro Med Systems holds a recent Real Value of $5.35 per share. The prevailing price of the company is $4.37. Our model determines the value of Repro Med Systems from analyzing the company fundamentals such as Shares Outstanding of 46.32 M, operating margin of (0.08) %, and Return On Equity of -0.22 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Repro Med's valuation include:
Price Book 13.1387 | Enterprise Value | Enterprise Value Ebitda (17.15) | Price Sales 5.5368 | Forward PE 188.6792 |
Undervalued
Today
Please note that Repro Med's price fluctuation is slightly risky at this time. Calculation of the real value of Repro Med Systems is based on 3 months time horizon. Increasing Repro Med's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Repro stock is determined by what a typical buyer is willing to pay for full or partial control of Repro Med Systems. Since Repro Med is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Repro Stock. However, Repro Med's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.37 | Real 5.35 | Target 6.6 | Hype 4.34 |
The real value of Repro Stock, also known as its intrinsic value, is the underlying worth of Repro Med Systems Company, which is reflected in its stock price. It is based on Repro Med's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Repro Med's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Repro Med Systems helps investors to forecast how Repro stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Repro Med more accurately as focusing exclusively on Repro Med's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Repro Med's intrinsic value based on its ongoing forecasts of Repro Med's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Repro Med's closest peers. If more than one evaluation category is relevant for Repro Med we suggest using both methods to arrive at a better estimate.
Repro Med Cash |
|
Repro Med Total Value Analysis
Repro Med Systems is now expected to have valuation of 211.54 M with market capitalization of 216.33 M, debt of 3.99 M, and cash on hands of 18.27 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Repro Med fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
211.54 M | 216.33 M | 3.99 M | 18.27 M |
Repro Med Investor Information
About 57.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.08. Repro Med Systems had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from Repro Med's historical financial statements, Repro Med Systems is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Repro Med Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Repro Med has an asset utilization ratio of 123.62 percent. This indicates that the Company is making $1.24 for each dollar of assets. An increasing asset utilization means that Repro Med Systems is more efficient with each dollar of assets it utilizes for everyday operations.Repro Med Profitability Analysis
Based on the measurements of profitability obtained from Repro Med's financial statements, Repro Med Systems may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Repro Med's ability to earn profits and add value for shareholders.Net Loss | First Reported 2000-03-31 | Previous Quarter -206.9 K | Current Value -778 K | Quarterly Volatility 1 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.46 | 0.57 |
|
|
For Repro Med profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Repro Med Systems to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Repro Med utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Repro Med's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Repro Med over time as well as its relative position and ranking within its peers.
Repro Med Earnings per Share Projection vs Actual
The next projected EPS of Repro Med is estimated to be 0.00375 with future projections ranging from a low of -0.005 to a high of 0.015. Repro Med's most recent 12-month trailing earnings per share (EPS TTM) is at -0.08. Please be aware that the consensus of earnings estimates for Repro Med Systems is based on EPS before non-recurring items and includes expenses related to employee stock options.Repro Med Earnings Estimation Breakdown
The calculation of Repro Med's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Repro Med is estimated to be 0.00375 with the future projection ranging from a low of -0.005 to a high of 0.015. Please be aware that this consensus of annual earnings estimates for Repro Med Systems is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.005 Lowest | Expected EPS | 0.01 Highest |
Repro Med Earnings Projection Consensus
Suppose the current estimates of Repro Med's value are higher than the current market price of the Repro Med stock. In this case, investors may conclude that Repro Med is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Repro Med's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 5 | 61.56% | 0.0 | 0.00375 | -0.08 |
Repro Med Ownership Allocation
Repro Med owns a total of 46.32 Million outstanding shares. Over half of Repro Med's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Repro Med Profitability Analysis
The company reported the previous year's revenue of 33.65 M. Net Loss for the year was (6.07 M) with profit before overhead, payroll, taxes, and interest of 24.35 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Repro Med's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Repro Med and how it compares across the competition.
About Repro Med Valuation
The stock valuation mechanism determines Repro Med's current worth on a weekly basis. Our valuation model uses a comparative analysis of Repro Med. We calculate exposure to Repro Med's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Repro Med's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 24.5 M | 25.8 M | |
| Pretax Profit Margin | (0.21) | (0.20) | |
| Operating Profit Margin | (0.22) | (0.21) | |
| Net Loss | (0.21) | (0.20) | |
| Gross Profit Margin | 0.57 | 0.46 |
Repro Med Growth Indicators
Investing in growth stocks can be very risky. If the company such as Repro Med does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 45.8 M | |
| Quarterly Earnings Growth Y O Y | -0.66 | |
| Forward Price Earnings | 188.6792 |
Repro Med Current Valuation Indicators
Valuation refers to the process of determining the present value of Repro Med Systems and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Repro we look at many different elements of the entity such as Repro's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Repro Med, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Repro Med's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Repro Med's worth.Complementary Tools for Repro Stock analysis
When running Repro Med's price analysis, check to measure Repro Med's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repro Med is operating at the current time. Most of Repro Med's value examination focuses on studying past and present price action to predict the probability of Repro Med's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repro Med's price. Additionally, you may evaluate how the addition of Repro Med to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |